Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 4 of the 12 sources its claims cite were checked for support.
Abstract
Common recommendations for cell line authentication, annotation and quality control fall short addressing genetic heterogeneity. Within the Human Toxome Project, we demonstrate that there can be marked cellular and phenotypic heterogeneity in a single batch of the human breast adenocarcinoma cell line MCF-7 obtained directly from a cell bank that are invisible with the usual cell authentication by short tandem repeat (STR) markers. STR profiling just fulfills the purpose of authentication testing, which is to detect significant cross-contamination and cell line misidentification. Heterogeneity needs to be examined using additional methods. This heterogeneity can have serious consequences for reproducibility of experiments as shown by morphology, estrogenic growth dose-response, whole genome gene expression and untargeted mass-spectroscopy metabolomics for MCF-7 cells. Using Comparative Genomic Hybridization (CGH), differences were traced back to genetic heterogeneity already in the cells from the original frozen vials from the same ATCC lot, however, STR markers did not differ from ATCC reference for any sample. These findings underscore the need for additional quality assurance in Good Cell Culture Practice and cell characterization, especially using other methods such as CGH to reveal possible genomic heterogeneity and genetic drifts within cell lines.
Overview
CoChat Summary
TL;DR
MCF-7 cells from the same ATCC lot and with matching STR profiles showed marked phenotypic, transcriptomic, metabolomic, and genomic heterogeneity between two laboratories. This heterogeneity was already present in DNA from original frozen vials and affected key functional outcomes such as estradiol-driven proliferation.
Key findings
- Two laboratories (BU and JHU) using MCF-7 from the same ATCC lot (lot 59388743, passage 147) and identical STR profiles for all 9 typed markers observed different phenotypes: BU cells grew in large aggregations, while JHU cells grew flat with cobblestone morphology.
- After 72 h exposure to estradiol, BU MCF-7 cells showed significant increases in proliferation at 0.1, 1, and 10 nM, whereas JHU cells showed no significant change; PPT exposure similarly increased proliferation in BU cells at 0.1, 1.0, and 10 nM but not in JHU cells.
- Untargeted metabolomics PCA of 1048 features separated the two sublines and showed differential response to E2; microarray PCA showed transcriptional differences already in untreated control cells, and an 84-gene heat map clustered the sublines separately.
- CGH detected almost the same significant genomic differences on chromosomes 1, 3, 4, 5, 7, 8, 9, 10, 13, 15, 20, and X in DNA directly prepared from two original never-thawed ATCC vials from the same lot as after a few passages in culture, while STR markers did not differ from the ATCC reference for any sample.
Methods
- MCF-7 cells from the same ATCC lot were obtained by Brown University and Johns Hopkins University; one vial per lab was grown using identical protocols and Good Cell Culture Practice, with experiments performed at passage 3 (BU) and passage 8 (JHU), while a second vial per lab remained never thawed.
- Assays included morphologic high-content imaging, estradiol/PPT proliferation and qRT-PCR for progesterone receptor, Agilent whole-genome gene expression microarrays, untargeted LC-MS metabolomics, Comparative Genomic Hybridization (CGH), and STR profiling.
- Analyses included two-way ANOVA, principal component analysis, unsupervised hierarchical clustering, and CGH aberration detection with ADM-2 threshold 10; CGH and STR experiments were performed in one laboratory by one individual.
Limitations
- The paper does not state a dedicated limitations section; it acknowledges that current authentication methods do not preclude genetic heterogeneity and that combining omics technologies does not overcome the limitations of tumor cell lines.
- Evident from the text: the study compares only two laboratories and one ATCC lot of MCF-7, so the generalizability to other cell lines, lots, or laboratories is not directly tested, although the authors suggest MCF-7 is likely not unique.
- Some verification experiments are reported only as “data not shown” (cells exchanged between laboratories), limiting independent assessment of those results.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
4 Valid · 1 Not valid · 2 Not checked · 31 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In this respect, MCF-7 are likely not unique. For example, studies with T47D - the second most commonly used cell line as an in vitro breast cancer model - as well as others20 suggest similar genotypic and phenotypic heterogeneity212223.”
§ Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function > Discussion
What the sources say
- Partly supportedcites [20] Rondon-Lagos M. et al. Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis. Molecular cytogenetics 7, 8 (2014). 24456987 PMC3914704 sourceExperimental — accuracy not yet measured
The Results section on T47D cells (page unavailable) reports variation in chromosomal abnormalities among its 24 metaphases, supporting the point that cytogenetic heterogeneity is not unique to MCF-7. It does not establish phenotypic heterogeneity within T47D, which the citing sentence also attributes to the cited studies. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [21] Graham M. L. 2nd, Smith J. A., Jewett P. B. & Horwitz K. B. Heterogeneity of progesterone receptor content and remodeling by tamoxifen characterize subpopulations of cultured human breast cancer cells: analysis by quantitative dual parameter flow cytometry. Cancer Res 52, 593– 602 (1992). 1732047
- Not checked — no full text of the sourcecites [22] Hughes P., Marshall D., Reid Y., Parkes H. & Gelber C. The costs of using unauthenticated, over-passaged cell lines: how much more data do we need? BioTechniques 43, 575, 577–578, 581–572 passim (2007). 18072586 source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For example, studies with T47D - the second most commonly used cell line as an in vitro breast cancer model - as well as others20 suggest similar genotypic and phenotypic heterogeneity212223.”
§ Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function > Discussion
What the sources say
- Partly supportedcites [20] Rondon-Lagos M. et al. Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis. Molecular cytogenetics 7, 8 (2014). 24456987 PMC3914704 sourceExperimental — accuracy not yet measured
The Results section on T47D reports chromosomal alterations that vary among its metaphases, and the comparison of four cell lines reports distinct chromosomal patterns. These support genotypic heterogeneity, but the paper does not demonstrate phenotypic heterogeneity within T47D or the other cell lines. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [21] Graham M. L. 2nd, Smith J. A., Jewett P. B. & Horwitz K. B. Heterogeneity of progesterone receptor content and remodeling by tamoxifen characterize subpopulations of cultured human breast cancer cells: analysis by quantitative dual parameter flow cytometry. Cancer Res 52, 593– 602 (1992). 1732047
- Not checked — no full text of the sourcecites [22] Hughes P., Marshall D., Reid Y., Parkes H. & Gelber C. The costs of using unauthenticated, over-passaged cell lines: how much more data do we need? BioTechniques 43, 575, 577–578, 581–572 passim (2007). 18072586 source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This heterogeneity can have serious consequences for reproducibility of experiments as shown by morphology, estrogenic growth dose-response, whole genome gene expression and untargeted mass-spectroscopy metabolomics for MCF-7 cells.”
- Also stated in: § Discussion · plain
“Even simple outcomes, such as estradiol dose-response, can be divergent between two laboratories using what appear to be the “same” cells and the same protocol.”
§ Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Gene expression analysis using quantitative PCR of the estrogen receptor target progesterone receptor (PgR) following 6 hours of exposure to E2 indicated that BU MCF-7 cells are responsive to low levels of estrogen (Fig. 1C).”
§ Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function > Results
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Technical replicates of MCF-7 genomic DNA from MCF-7 cells being used for experiments after a few passages hybridized against human Caucasian female reference DNA showed only small differences of short length, which are simply expected by statistical chance because of the >100,000 involved CGH probes (Fig. 5).”
§ Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function > Results
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
7 more claims
Create a free account to see all 38 claims and every source verdict.
- It may state two separate claims as one. 16
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Systematic investigations revealed significant genetic differences in widely applied cell models between different laboratories (Frattini et al., 2015; Kleensang et al., 2016; Gutbier et al., 2018).”
From In Vitro research Reproducibility: Keeping up High Standards (2019) · cites this paper as Kleensang et al., 2016
Citations
Cites
KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
Pluskal, T., Castillo, S., Villar-Briones, A., & Orešič, M. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-395 · Cited by 3,845
HMDB: the Human Metabolome Database
Wishart, D. S., Tzur, D., Knox, C., Eisner, R., Guo, A. C., Young, N., Cheng, D., Jewell, K., Arndt, D., Sawhney, S., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl923 · Cited by 3,231
A Human Cell Line From a Pleural Effusion Derived From a Breast Carcinoma 2
Soule, H. D., Vazquez, J., Long, A., Albert, S., & Brennan, M. (1973) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/51.5.1409 · Cited by 2,449
International Journal of Oncology
(2026) · International Journal of Oncology · doi:10.3892/ijo · Cited by 2,331
ProteoWizard: open source software for rapid proteomics tools development
Kessner, D., Chambers, M., Burke, R., Agus, D., & Mallick, P. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn323 · Cited by 2,024
The Costs of using Unauthenticated, Over-Passaged Cell Lines: How Much more Data do we Need?
Hughes, P., Marshall, D., Reid, Y., Parkes, H., & Gelber, C. (2007) · BioTechniques · doi:10.2144/000112598 · Cited by 434
Coecke, S., Balls, M., Bowe, G., Davis, J., Gstraunthaler, G., Hartung, T., Hay, R., Merten, O.-W., Price, A., Schechtman, L., et al. (2005) · Alternatives to Laboratory Animals · doi:10.1177/026119290503300313 · Cited by 371
A resource for cell line authentication, annotation and quality control
Yu, M., Selvaraj, S. K., Liang-Chu, M. M. Y., Aghajani, S., Busse, M., Yuan, J., Lee, G., Peale, F., Klijn, C., Bourgon, R., et al. (2015) · Nature · doi:10.1038/nature14397 · Cited by 225
Cited by
Poynton, F. E., Bright, S. A., Blasco, S., Williams, D. C., Kelly, J. M., & Gunnlaugsson, T. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00680b · Cited by 421
Toxicity testing in the 21st century: progress in the past decade and future perspectives
Krewski, D., Andersen, M. E., Tyshenko, M. G., Krishnan, K., Hartung, T., Boekelheide, K., Wambaugh, J. F., Jones, D., Whelan, M., Thomas, R., et al. (2020) · Archives of Toxicology · doi:10.1007/s00204-019-02613-4 · Cited by 383
Self-citationMulti-omic measurements of heterogeneity in HeLa cells across laboratories
Liu, Y., Mi, Y., Mueller, T., Kreibich, S., Williams, E. G., Van Drogen, A., Borel, C., Frank, M., Germain, P.-L., Bludau, I., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0037-y · Cited by 338
Genomic evolution of cancer models: perils and opportunities
Ben-David, U., Beroukhim, R., & Golub, T. R. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0095-3 · Cited by 222
High-Throughput Transcriptomics Platform for Screening Environmental Chemicals
Harrill, J. A., Everett, L. J., Haggard, D. E., Sheffield, T., Bundy, J. L., Willis, C. M., Thomas, R. S., Shah, I., & Judson, R. S. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab009 · Cited by 186
In Vitro research Reproducibility: Keeping up High Standards
Hirsch, C., & Schildknecht, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01484 · Cited by 161
Guidance Document on Good In Vitro Method Practices (GIVIMP)
OECD (2018) · OECD Series on Testing and Assessment · doi:10.1787/9789264304796-en · Cited by 161
Good Cell Culture Practice for stem cells and stem-cell-derived models
Pamies, D. (2016) · ALTEX · doi:10.14573/altex.1607121 · Cited by 160
“…Sekino 14 , Yasunari Kanda 14 , Lena Smirnova 1 and Thomas Hartung 1,10 1 Center for Alternatives to Animal Testing, Johns Hopkins University, Baltimore, MD, USA; Pamies et al. ALTEX 34(1), 2017 96 (not detectable with STR) were found in cultures from a major cell bank (Kleensang et al., 2016).”
BackgroundPamies, D. (2018) · ALTEX · doi:10.14573/altex.1710081 · Cited by 127
21st Century Cell Culture for 21st Century Toxicology
Pamies, D., & Hartung, T. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00269 · Cited by 118
Self-citationPerspectives on In Vitro to In Vivo Extrapolations
Härtung, T. (2017) · Applied In Vitro Toxicology · doi:10.1089/aivt.2016.0026 · Cited by 100
“Tumor origin of many cells: dramatic genetic instability is still frequently not taken into consideration, contributing to irreproducible results.(35) Cell identity: it is difficult to believe, but work is still carried out quite frequently (up to 25% of studies) with cell lines that are not what they are supposed to…”
BackgroundSelf-citationhttps://www.altex.org/index.php/altex/article/view/1339
Krebs, A., Waldmann, T., Wilks, M. F., van Vugt-Lussenburg, B. M. A., van der Burg, B., Terron, A., Steger-Hartmann, T., Ruegg, J., Rovida, C., Pedersen, E., et al. (2019) · ALTEX · doi:10.14573/altex.1909271 · Cited by 77
Self-citationHorrigan, S. K., & Reproducibility Project: Cancer Biology (2017) · eLife · doi:10.7554/elife.18173 · Cited by 72
“These include variables such as cell line genetic drift (Hughes et al., 2007; Kleensang et al., 2016), circadian biological responses to therapy (Fu and Kettner, 2013), mouse strain stocks (Clayton and Collins, 2014), housing temperature in mouse facilities (Kokolus et al., 2013), and the obesity…”
BackgroundReardon, A. J. F., Farmahin, R., Williams, A., Meier, M. J., Addicks, G. C., Yauk, C. L., Matteo, G., Atlas, E., Harrill, J., Everett, L. J., et al. (2023) · Frontiers in Toxicology · doi:10.3389/ftox.2023.1194895 · Cited by 85
“Further to this, immortalized and transformed cell lines that have abnormal/unstable karyotypes may not produce the transcriptomic responses that are consistent with expected responses in normal human tissues (Kleensang et al., 2016).”
BackgroundThe Ascendance of Microphysiological Systems to Solve the Drug Testing Dilemma
Dehne, E.-M., Hasenberg, T., & Marx, U. (2017) · Future Science OA · doi:10.4155/fsoa-2017-0002 · Cited by 68
Vaughan, L., Glänzel, W., Korch, C., & Capes-Davis, A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2258 · Cited by 63
Kassotis, C. D., Masse, L., Kim, S., Schlezinger, J. J., Webster, T. F., & Stapleton, H. M. (2017) · Scientific Reports · doi:10.1038/srep42104 · Cited by 61
Kassotis, C. D., & Stapleton, H. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00039 · Cited by 65
“This issue with cell line integrity was highlighted in a recent paper (208), suggesting that these differences can contribute to real discrepancies in the ability to replicate findings across laboratories.”
BackgroundOECD (2018) · OECD series on testing and assessment · doi:10.1787/9789264304796-1-en · Cited by 54
Desaulniers, D. M., Vasseur, P., Jacobs, A. C., Aguila, M. C., Ertych, N., & Jacobs, M. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010969 · Cited by 60
Gutbier, S., May, P., Berthelot, S., Krishna, A., Trefzer, T., Behbehani, M., Efremova, L., Delp, J., Gstraunthaler, G., Waldmann, T., et al. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2326-5 · Cited by 49
Maertens, A., Tran, V. P., Kleensang, A., & Härtung, T. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00508 · Cited by 52
“This study is certainly not a definitive study of BPA molecular mechanisms: our conclusions cannot confidently be extrapolated to other tissue types, as BPA may have tissue specific effects; MCF-7 cells are prone to artifacts (Kleensang et al., 2016); and our study did not focus on epigenetic mechanisms which are spec…”
ResultSelf-citationReplication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
Aird, F., Kandela, I., Mantis, C., & Reproducibility Project: Cancer Biology (2017) · eLife · doi:10.7554/elife.21253 · Cited by 45
Kim, E., Kim, J.-Y., Smith, M. A., Haura, E. B., & Anderson, A. R. A. (2018) · PLOS Biology · doi:10.1371/journal.pbio.2002930 · Cited by 46
Chemical composition and cytotoxicity of Philippine calamansi essential oil
Palma, C. E., Cruz, P., Cruz, D. T. C., Bugayong, A. M., & Castillo, A. L. (2018) · Industrial Crops and Products · doi:10.1016/j.indcrop.2018.11.010 · Cited by 54
Obesity III: Obesogen assays: Limitations, strengths, and new directions
Kassotis, C. D., Saal, F. S. V., Babin, P. J., Lagadic‐Gossmann, D., Mentec, H. L., Blumberg, B., Mohajer, N., Legrand, A., Kos, V. M., Martin‐Chouly, C., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115014 · Cited by 51
“These and other cell line integrity issues can contribute to discrepancies in replication efforts between laboratories [34,35].”
Wildtype heterogeneity contributes to clonal variability in genome edited cells
Westermann, L., Li, Y., Göçmen, B., Niedermoser, M., Rhein, K., Jahn, J., Cascante, I., Schöler, F., Moser, N., Neubauer, B., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-22885-8 · Cited by 61
Replication Study: Transcriptional amplification in tumor cells with elevated c-Myc
Lewis, L. M., Edwards, M. C., Meyers, Z. R., Talbot, C. C., Hao, H., Blum, D., Reproducibility Project: Cancer Biology, Iorns, E. J., Tsui, R., Denis, A., et al. (2018) · eLife · doi:10.7554/elife.30274 · Cited by 45
“These include variables such as cell line genetic drift (Hughes et al., 2007; Kleensang et al., 2016) or changes in cellular volume that can impact overall transcript abundance (Padovan-Merhar et al., 2015).”
BackgroundAssessment of Genetic Drift in Large Pharmacogenomic Studies
Quevedo, R., Smirnov, P., Tkachuk, D., Ho, C., El-Hachem, N., Safikhani, Z., Pugh, T. J., & Haibe‐Kains, B. (2020) · Cell Systems · doi:10.1016/j.cels.2020.08.012 · Cited by 45
Kassotis, C. D., Hoffman, K., Völker, J., Pu, Y., Veiga‐Lopez, A., Kim, S. M., Schlezinger, J. J., Bovolin, P., Cottone, E., Saraceni, A., et al. (2021) · Toxicology · doi:10.1016/j.tox.2021.152900 · Cited by 39
Yan, X., Tang, B., Chen, B., Shan, Y., Yang, H., Reproducibility Project: Cancer Biology, Iorns, E. J., Tsui, R., Denis, A., Perfito, N., et al. (2019) · eLife · doi:10.7554/elife.43511 · Cited by 35
“These include variables such as cell line genetic drift (Ben-David et al., 2018; Hughes et al., 2007; Kleensang et al., 2016), subclonal drift in heterogeneous stable cells (Shearer and Saunders, 2015), genetic heterogeneity of mouse inbred strains (Casellas, 2011), and the microbiome of recipient mice (Macpherson and…”
BackgroundReplication Study: Melanoma genome sequencing reveals frequent PREX2 mutations
Horrigan, S. K., Courville, P., Sampey, D. B., zhou, F., Cai, S., & Reproducibility Project: Cancer Biology (2017) · eLife · doi:10.7554/elife.21634 · Cited by 34
“…PREX2 copy number in transformed cells, circadian biological responses to therapy (Fu and Kettner, 2013), the microbiome of recipient mice (Macpherson and McCoy, 2015), housing temperature in mouse facilities (Kokolus et al., 2013), and cell line drift (Hughes et al., 2007; Kleensang et al., 2016).”
BackgroundMajor multilevel molecular divergence between THP‐1 cells from different biorepositories
Noronha, N., Ehx, G., Meunier, M., Laverdure, J., Thériault, C., & Perreault, C. (2020) · International Journal of Cancer · doi:10.1002/ijc.32967 · Cited by 48
Barata, I. S., Gomes, B. C., Rodrigues, A. S., Rueff, J., Kranendonk, M., & Esteves, F. (2022) · Genes · doi:10.3390/genes13111977 · Cited by 31
Krebs, A. (2020) · ALTEX · doi:10.14573/altex.1909271e · Cited by 31
Härtung, T. (2021) · ALTEX · doi:10.14573/altex.2101051 · Cited by 41
“Our own experience with other cell lines like MCF-7 (Kleensang et al., 2015) and that of others for HeLa cells (Frattini et al.”
BackgroundSelf-citationMicrofluidic Platform for Profiling of Extracellular Vesicles from Single Breast Cancer Cells
Nikoloff, J. M., Saucedo‐Espinosa, M. A., & Dittrich, P. S. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c04106 · Cited by 30
Kalimuthu, A. K., Pavadai, P., Theivendren, P., Babkiewicz, E., Pijanowska, J., Mrówka, P., Rajagopal, G., Deepak, V., Sundar, K., Maszczyk, P., et al. (2022) · Molecules · doi:10.3390/molecules27248814 · Cited by 34
“The cells were frequently tested against mycoplasma according to the laboratory protocol [27].”
MethodReplication Study: Systematic identification of genomic markers of drug sensitivity in cancer cells
Heuvel, J. P. V., Maddox, E., Maalouf, S. W., Reproducibility Project: Cancer Biology, Iorns, E. J., Tsui, R., Denis, A., Perfito, N., & Errington, T. M. (2018) · eLife · doi:10.7554/elife.29747 · Cited by 31
“These include variables such as cell line genetic drift (Hughes et al., 2007; Kleensang et al., 2016), sex of cell lines (Clayton and Collins, 2014), impacts of atmospheric oxygen on cell viability and growth (Boregowda et al., 2012), and differing Vanden Heuvel et al. eLife 2018;7:e29747.”
BackgroundKim, J., Afshari, A., Sengupta, R., Sebastiano, V., Gupta, A. A., Kim, Y. H., Reproducibility Project: Cancer Biology, Iorns, E. J., Tsui, R., Denis, A., et al. (2018) · eLife · doi:10.7554/elife.39944 · Cited by 30
Jain, N., Nitisa, D., Pirsko, V., & Cakstina, I. (2020) · BMC Molecular and Cell Biology · doi:10.1186/s12860-020-00313-x · Cited by 29
“Lastly, given the widespread use of cancer cell lines not only for basic research but also for drug development and regulatory decision making, ensuring that sub-clones among the cell line are adequately standardized in their expression behavior tends to represent a challenging path forward [16].”
BackgroundInfluentialFiehn, O., Showalter, M. R., Tooley, C. E. S., & Reproducibility Project: Cancer Biology (2016) · eLife · doi:10.7554/elife.12626 · Cited by 25
Sheen, M. R., Fields, J. L., Northan, B., Lacoste, J., Ang, L., Fiering, S., Reproducibility Project: Cancer Biology, Iorns, E. J., Tsui, R., Denis, A., et al. (2019) · eLife · doi:10.7554/elife.45120 · Cited by 26
“These include variables such as cell line genetic drift (Ben-David et al., 2018; Hughes et al., 2007; Kleensang et al., 2016), including subclonal drift in heterogeneous stable cells (Shearer and Saunders, 2015), genetic heterogeneity of mouse inbred strains (Casellas, 2011), the microbiome of recipient mice (Macphers…”
BackgroundEssex, A., Pineda, J. J., Acharya, G., Xin, H., Evans, J., Reproducibility Project: Cancer Biology, Iorns, E. J., Tsui, R., Denis, A., Perfito, N., et al. (2019) · eLife · doi:10.7554/elife.45426 · Cited by 23
Fasterius, E., & Szigyarto, C. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-29506-3 · Cited by 24
Best practices for authenticating cell lines
Nims, R. W., & Reid, Y. (2017) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-017-0212-8 · Cited by 21
“Cell phenotype can change as a result of changes in culture conditions, or as a result of genetic heterogeneity (Frattini et al. 2015; Kleensang et al. 2016).”
BackgroundGenetic instability of in vitro cell lines: Implications for genetic toxicity testing
Li, J., Settivari, R. S., & LeBaron, M. J. (2019) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22280 · Cited by 24
“There is a longstanding and general awareness that genetic variation exists in cell lines [Frattini et al. 2015; Kleensang et al. 2016]; however, a recent study elucidated the astonishing magnitude of cell line genetic drift and variance [Ben-David et al.”
BackgroundAcademic application of Good Cell Culture Practice for induced pluripotent stem cells
Tigges, J. (2021) · ALTEX · doi:10.14573/altex.2101221 · Cited by 19
“Nevertheless, another drawback of these high-resolution methods is that while they provide a lot of data, they lack a definition of what differences may impact the reproducibility of research (Kleensang et al., 2016).”
BackgroundShan, X., Fung, J. J., Kosaka, A. H., Danet-Desnoyers, G. A., & Reproducibility Project: Cancer Biology (2017) · eLife · doi:10.7554/elife.25306 · Cited by 18
“These include variables such as cell line genetic drift (Hughes et al., 2007; Kleensang et al., 2016), mouse sex (Clayton and Collins, 2014), circadian biological responses to therapy (Fu and Kettner, 2013), the microbiome of recipient mice Meta−analysis RP:CB (n = 6 ) Dawson et al.”
BackgroundMethodZhang, X., Peng, Y., & Wu, C. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.112038 · Cited by 18
Showalter, M. R., Hatakeyama, J., Čajka, T., VanderVorst, K., Carraway, K. L., Fiehn, O., & Reproducibility Project: Cancer Biology (2017) · eLife · doi:10.7554/elife.26030 · Cited by 21
“These include variables such as cell line genetic drift (Hughes et al., 2007; Kleensang et al., 2016), GC-MS parameters such as injection volume (Allwood et al., 2009), and other patient characteristics (Klevorn and Teague, 2016).”
BackgroundKorch, C. T., & Varella‐Garcia, M. (2018) · Advances in Molecular Pathology · doi:10.1016/j.yamp.2018.07.003 · Cited by 19
McGovern, J., Bock, N., Shafiee, A., Martine, L. C., Wagner, F., Baldwin, J., Landgraf, M., Lahr, C. A., Meinert, C., Williams, E. D., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02527-x · Cited by 16
Ntai, A., Baronchelli, S., Spada, A., Moles, A., Guffanti, A., Blasio, P. D., & Biunno, I. (2017) · Biopreservation and Biobanking · doi:10.1089/bio.2016.0097 · Cited by 15
Corrêa, N. C. R., Kuligovski, C., Paschoal, A. C. C., Abud, A. P. R., Rebelatto, C. L. K., Leite, L. M. B., Senegaglia, A. C., Dallagiovanna, B., & de Aguiar, A. M. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.11.004 · Cited by 14
60 Years of the 3Rs symposium: Lessons learned and the road ahead
Balls, M., Baß, R., Curren, R. D., helen, F. J., Goldberg, A. M., Härtung, T., Herrmann, K., Kleinstreuer, N., Libowitz, L. A., Parascandola, J., et al. (2024) · ALTEX · doi:10.14573/altex.2403061 · Cited by 19
“Other cell lines are infected or have genetic instability (Kleensang et al., 2016).”
BackgroundSelf-citationDittmer, A., & Dittmer, J. (2018) · Oncotarget · doi:10.18632/oncotarget.25183 · Cited by 14
“MCF-7 cell line heterogeneity has also been reported by others [40, 41].”
BackgroundKerwin, J., Khan, I., Reproducibility Project: Cancer Biology, Iorns, E. J., Tsui, R., Denis, A., Perfito, N., & Errington, T. M. (2020) · eLife · doi:10.7554/elife.51019 · Cited by 17
“These include variables such as cell line genetic drift (Hughes et al., 2007; Kleensang et al., 2016), and impacts of atmospheric oxygen on cell viability and growth (Boregowda et al.”
BackgroundMyint, L., Kleensang, A., Zhao, L., et al. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04719 · Cited by 12
Self-citationChallenges and opportunities for strain verification by whole-genome sequencing
Gallegos, J. E., Häyrynen, S., Adames, N. R., & Peccoud, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-62364-6 · Cited by 12
Rižner, T. L., & Adamski, J. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.12.017 · Cited by 11
Petkidis, A., Suomalainen, M., Andriasyan, V., Singh, A., & Greber, U. F. (2024) · mSphere · doi:10.1128/msphere.00454-24 · Cited by 9
“As previous reports demonstrated that cancer cell lines display considerable genetic heterogeneity (38–40), we started our investigation by isolating single cells and growing them in clonal founding populations.”
Tran, V. P., Kim, R., Maertens, M., Härtung, T., & Maertens, A. (2021) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2021.674370 · Cited by 16
Self-citationShakya, R., Jiménez‐Meléndez, A., Robertson, L. J., & Myrmel, M. (2021) · Microbes and Infection · doi:10.1016/j.micinf.2021.104909 · Cited by 8
Ugur, D., Güngül, T. B., Yucel, S., et al. (2022) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-021-00665-9 · Cited by 8
Wang, H., Radomska, H. S., Phelps, M. A., Reproducibility Project: Cancer Biology, Iorns, E. J., Tsui, R., Denis, A., Perfito, N., & Errington, T. M. (2020) · eLife · doi:10.7554/elife.56651 · Cited by 9
G × E interactions as a basis for toxicological uncertainty
Suciu, I., Pamies, D., Peruzzo, R., Wirtz, P. H., Smirnova, L., Pallocca, G., Hauck, C. R., Cronin, M., Hengstler, J. G., Brunner, T., et al. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03500-9 · Cited by 16
“For instance, we (Kleensang et al. 2016) observed major differences in the transcriptional response to oestrogen in MCF-7 cells from different frozen vials.”
BackgroundSelf-citationChallenges and Advances in the Development of Cell Lines and Xenografts
Schweppe, R. E., & Korch, C. T. (2018) · Advances in Molecular Pathology · doi:10.1016/j.yamp.2018.07.004 · Cited by 7
Valle, A. C. V., Aguiar, L. R., Brunel, H. D. S. S., et al. (2021) · International Journal of High Dilution Research · doi:10.51910/ijhdr.v19i4.1036 · Cited by 5
“In vitro product safety assessment studies involve cytotoxicity analysis, in which the main cell models used are primary cell cultures and strains [25,26].”
BackgroundOlayoku, F. R., Verhoog, N. J. D., & Louw, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1122031 · Cited by 5
“(2015) and Power and Thompson (2003), respectively, may be due to the variations in the genotypes of the cell lines used by the different laboratories, the difference in the concentrations of the test compounds and experimental procedures such as different time points used for test compound treatment, as well as diffe…”
BackgroundAutomation and opportunities for industry scale-up of microphysiological systems
Dehne, E., Erfurth, H., Muhsmann, A.-K., & Marx, U. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817202-5.00014-0 · Cited by 6
Weng, W., Wang, C.-Y., Yan, Z.-Y., Lee, H.-T., Kao, C., & Chang, C. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115985 · Cited by 5
Metabolomics applied to cultured human and animal cells
Artati, A., & Tokarz, J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-812784-1.00008-6 · Cited by 4
Pelech, S., Gallagher, C., Sutter, C., Yue, L., Kerwin, J., Bhargava, A., Iorns, E. J., Tsui, R., Denis, A., Perfito, N., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.30.470372 · Cited by 4
“These include variables such as cell line genetic drift (Hughes et al., 2007; Kleensang et al., 2016), differing compound potency resulting from different stock solutions (Kannt and Wieland, 2016), and lot to lot variability of reagents (Leek et al., 2010).”
BackgroundŽymantaitė, E., Gabrielaitė, M., Pašukonienė, V., & Mlynska, A. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052451 · Cited by 3
“However, standard authentication methods, such as STR, do not consider the genetic and functional diversity within a cell line, which can significantly compromise reproducibility across experiments or laboratories (Ben-David et al., 2018; Kleensang et al., 2016).”
A user guide to RT-based mapping of RNA modifications
Fang, D., Babich, J. M., Dangelmaier, E. A., Wall, V., & Nachtergaele, S. (2024) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2024.07.006 · Cited by 2
Crispim, D., Ramos, C., Esteves, F., & Kranendonk, M. (2025) · Metabolites · doi:10.3390/metabo15020136 · Cited by 5
“…in transcriptional Nota-bly, arachidonic acid metabolism and subsequent eicosanoid synthesis have previously been linked to the release of growth factors, angiogenic factors, and pro-inflammatory regulators [59–61]. regulation linked to metabolic reprogramming in response to DOX exposure [53,54].”
Plasmalogen mediates integration of adherens junction
Takahashi, T., Honsho, M., Abe, Y., & Fujiki, Y. (2019) · The Journal of Biochemistry · doi:10.1093/jb/mvz049 · Cited by 3
Muzzi, J. C. D., Ruggiero, C., Doghman, M., Colodel, M. E., Magno, J. M., Resende, J. S. S., Durand, N., de Moura, J. F., Alvarenga, L. M., Cavalli, L. R., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf138 · Cited by 2
Korch, C. T. (2026) · Current Protocols · doi:10.1002/cpz1.70387 · Cited by 2
Valle, A. C. V., Aguiar, L. R., Brunel, H. D. S. S., Malard, P. F., & de Andrade, R. V. (2020) · International Journal of Homoeopathic Sciences · doi:10.33545/26164485.2020.v4.i2d.179 · Cited by 4
Krebs, A. (2019) · ALTEX · doi:10.14573/altex.1909271s · Cited by 19
“Even two batches of cells from a single source can differ significantly (Ben-David et al., 2018; Frattini et al., 2015; Kleensang et al., 2016; Liu et al., 2019).”
BackgroundGood Cell Culture Practice (GCCP)
OECD (2018) · OECD series on testing and assessment · doi:10.1787/9789264304796-16-en · Cited by 4
Test and reference/control items
OECD (2018) · OECD series on testing and assessment · doi:10.1787/9789264304796-11-en · Cited by 2
Tyrna, P., Kostro, J. M., Olszanecka, M., Szukało, P., & Młynarczuk-Biały, I. (2025) · Cells · doi:10.3390/cells14191500 · Cited by 1
“Both MCF7 and BxPC3 cell lines are wild-type with respect to RAS mutations, meaning they do not carry activating mutations in the RAS oncogene [23,24].”
Standardisation and accreditation bodies
OECD (2018) · OECD series on testing and assessment · doi:10.1787/9789264304796-20-en · Cited by 1
OECD (2018) · OECD series on testing and assessment · doi:10.1787/9789264304796-6-en · Cited by 1
Storage and retention of records and materials
OECD (2018) · OECD series on testing and assessment · doi:10.1787/9789264304796-15-en · Cited by 1
Integration of hyperspectral imaging and transcriptomics from individual cells with HyperSeqPreprint
Xie, Y., Habibalahi, A., Anwer, A. G., Wahi, K., Gatt, C., Johansson, E. M. V., Holst, J., Goldys, E. M., & Zanini, F. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.27.577536 · Cited by 1
“Multimodal characterisation of individual cells would benefit biomedical applications including cancer and infectious disease, given that both malignant and virus-infected cells can be genetically 17 , transcriptionally 18 , and metabolically 19 diverse within a single culture.”
BackgroundKaryotypic divergence confounds cellular phenotypes in large pharmacogenomic studiesPreprint
Quevedo, R., El-Hachem, N., Smirnov, P., Safikhani, Z., Pugh, T. J., & Haibe‐Kains, B. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/574350
The authenticity, sterility, and stability of culturing human pluripotent stem cells
Yoon, H.-J., & Ho, W. J. (2019) · Integrative Molecular Medicine · doi:10.15761/imm.1000361
Protection from Endoplasmic Reticulum Stress and Apoptosis via PPARδ and Bcl-2 in Breast Cancer
Wong, H. (2019) · TSpace (University of Toronto) · Cited by 1
iPSCs for modeling influenza infection
Amiri, A. Z., & Coombs, K. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823808-0.00011-0
Linhartová, L., Costet, N., Pakdel, F., Cajthaml, T., & Habauzit, D. (2021) · Journal of Applied Toxicology · doi:10.1002/jat.4280
“…assays employed in environmental sample evaluations are based on genetically modified estrogen receptorpositive cells transfected with the estrogen response element sequence with an appropriate detection marker (Adam et al., 2020; Legler et al., 1999; Leusch et al., 2017; Wilson et al., 2004).”
MethodOECD (2018) · OECD series on testing and assessment · doi:10.1787/9789264304796-14-en
List of viability testing methods (non-inclusive) of cell cultures
OECD (2018) · OECD series on testing and assessment · doi:10.1787/9789264304796-24-en · Cited by 1
OECD (2018) · OECD series on testing and assessment · doi:10.1787/9789264304796-13-en
Apparatus, material and reagents
OECD (2018) · OECD series on testing and assessment · doi:10.1787/9789264304796-9-en
OECD GIVIMP meeting 23-24 March, 2017 - participating experts
OECD (2018) · OECD series on testing and assessment · doi:10.1787/9789264304796-19-en
OECD (2018) · OECD series on testing and assessment · doi:10.1787/9789264304796-8-en
Metadata
- Authors
- Kleensang, A., Vantangoli, M. M., Odwin-DaCosta, S., Andersen, M. E., Boekelheide, K., Bouhifd, M., Fornace, A. J., Li, H.-H., Livi, C. B., Madnick, S., Maertens, A., Rosenberg, M., Yager, J. D., Zhao, L., & Hartung, T.
- Affiliations
- Brown University (US)
- Johns Hopkins University (US)
- The Hamner Institutes for Health Sciences (US)
- Georgetown University (US)
- Agilent Technologies (United States) (US)
- ORCID
- Venue
- Scientific Reports
- Published
- 2016-07-26
- Volume
- 6
- Issue
- 1
- Pages
- 28994-28994
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4960662
- OpenAlex
- W2493132014
- Cited by
- 114
- References
- 28
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 5 · 2023: 6 · 2022: 5 · 2021: 14 · 2020: 11 · 2019: 16 · 2018: 26 · 2017: 15 · 2016: 3
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Update notices
- erratum (2016-09-14)
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KOPS (University of Konstanz) (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- National Institute of Environmental Health Sciences (R01ES020750)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- MCF-7 cells, cell line authentication, genetic heterogeneity, short tandem repeat profiling, comparative genomic hybridization, genomic heterogeneity, genetic drift, gene expression profiling, metabolomics, reproducibility
- MeSH terms
- Genetic Markers, Humans, Genetic Variation, Reproducibility of Results, Microsatellite Repeats, Gene Expression Profiling, Cell Line, Tumor, Comparative Genomic Hybridization, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.